Zoledronic acid
- Generic Name
- Zoledronic acid
- Brand Names
- Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O7P2
- CAS Number
- 118072-93-8
- Unique Ingredient Identifier
- 70HZ18PH24
- Background
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid was first described in the literature in 1994.
Zoledronic acid was granted FDA approval on 20 August 2001.
- Indication
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
- Associated Therapies
- Bone Mineral Density
Denosumab vs Zoledronic Acid and Osteoporotic Compression Fracture
- Conditions
- Denosumab vs Zoledronate
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Shenzhen People's Hospital
- Target Recruit Count
- 122
- Registration Number
- NCT05106517
- Locations
- 🇨🇳
ShenzhenPH, Shenzhen, Guangdong, China
Romosozumab Use to Build Skeletal Integrity
- Conditions
- OsteoporosisOsteoporosis, PostmenopausalOsteoporosis Fracture
- Interventions
- First Posted Date
- 2021-09-28
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Susan L. Greenspan
- Target Recruit Count
- 200
- Registration Number
- NCT05058976
- Locations
- 🇺🇸
UPMC Senior Communities, Pittsburgh, Pennsylvania, United States
Zoledronic Acid for Prevention of Bone Loss After BAriatric Surgery (ZABAS)
- Conditions
- Bone LossMuscle AtrophyBariatric Surgery
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2022-06-10
- Lead Sponsor
- Stinus Gadegaard Hansen
- Target Recruit Count
- 60
- Registration Number
- NCT04742010
- Locations
- 🇩🇰
Hospital South West Jutland, Esbjerg, Denmark
Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 18028
- Registration Number
- NCT04736693
- Locations
- 🇺🇸
Brigham And Women's Hospital, Boston, Massachusetts, United States
CHronic Nonbacterial Osteomyelitis International Registry
- Conditions
- Chronic Recurrent Multifocal OsteomyelitisChronic Nonbacterial Osteomyelitis
- Interventions
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Seattle Children's Hospital
- Target Recruit Count
- 2000
- Registration Number
- NCT04725422
- Locations
- 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
Clinical Pharmacokinetics and Pharmacodynamics Study of Different Doses of Zoledronic Acid
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2021-06-23
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 64
- Registration Number
- NCT04719650
Effect of Zoledronic Acid on Prevention of Bone Loss in Acute Phase First-ever Stroke Patients
- First Posted Date
- 2020-12-03
- Last Posted Date
- 2020-12-03
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 56
- Registration Number
- NCT04652128
- Locations
- 🇰🇷
Yonsei Severance Hospital, Seoul, Korea, Republic of
Evaluation of Romosozumab vs. Zoledronic Acid Effect in Patients With Spinal Cord Injury and Low Bone Mineral Density
- Conditions
- Osteoporosis FractureSpinal Cord Injuries
- Interventions
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT04597931
Trochanteric Femur Fracture Operated With Dynamic Hip Screw System (DHS) Augmented With a Biphasic Apatite Sulphate Combined With Systemic or Local Bisphosphonate
- Conditions
- Trochanteric Fracture of Femur
- Interventions
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Lithuanian University of Health Sciences
- Target Recruit Count
- 20
- Registration Number
- NCT04498715
- Locations
- 🇱🇹
Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Kaunas, Lithuania
A Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-Small Cell Lung Cancer With Bone Metastasis
- Conditions
- Bone Metastatic Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-03-30
- Last Posted Date
- 2020-10-12
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT04325776
- Locations
- 🇨🇳
Anhui Chest Hospital, Hefei, Anhui, China
🇨🇳Quzhou People's Hospital, Quzhou, Zhejiang, China
🇨🇳China-Japan Union Hospital Of Jilin University, Changchun, Jilin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.